Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
H.C. Wainwright increased its price objective on Erasca Inc (NASDAQ: ERAS) to $15.00 from $11.00 and kept a Buy rating following preliminary clinical readouts from the AURORAS-1 study of ERAS-0015, a pan-RAS agent. The firm highlighted early partial responses observed at low dose levels and cited preclinical regressions in resistant tumor models. S…
H.C. Wainwright reduced its 12-month price target on electroCore Inc. to $18 from $25 while retaining a Buy rating. The adjustment follows electroCore's Jan. 20, 2026 preliminary results showing 2025 revenue of $31.8-$32.0 million, a 26% increase year-over-year, and fourth-quarter revenue of $9.0-$9.2 million, up 30% from Q4 2024. The analyst cited…
H.C. Wainwright increased its price target on BrainsWay (BWAY) to $30.00 from $24.00 while keeping a Buy rating, citing the company’s connection to Neurolief’s newly FDA-approved ProlivRx system and a small bump in the forward earnings multiple. The firm also factors $100 million of intrinsic value for BrainsWay’s strategic stake in Neurolief. Rece…
H.C. Wainwright raised its price target on Mirum Pharmaceuticals (MIRM) to $130.00 from $102.00 and kept a Buy rating, pointing to 2026 as a critical year for the company’s lead candidate volixibat. The stock has climbed sharply over the past year and recent preliminary sales results and multiple analyst actions have reinforced optimism about Mirum…
BofA Securities has reaffirmed a Buy rating on Regeneron Pharmaceuticals with a price target of $860, updating its financial model to incorporate the company's fourth-quarter Eylea pre-announcement, an IPR&D disclosure, a $60 million donation (bringing the total to $120 million), and 2026 R&D guidance. The firm projected strong Sanofi collaboration…
Needham upgraded AppLovin Corp (NASDAQ: APP) from Hold to Buy and set a $700 price target, implying roughly 33% upside from the stock's $524.41 level. The firm raised its 2026 ecommerce revenue forecast to $1.45 billion from $1.05 billion after additional analysis of AppLovin's ecommerce business and expects Q1 sequential growth as advertiser tract…
Once Upon a Farm has begun its investor roadshow for a planned initial public offering, filing to offer 10,997,209 shares of common stock and applying to list on the New York Stock Exchange under ticker OFRM. The offering includes primary shares, secondary shares from existing holders, an underwriter option, and an anticipated price range of $17 to…
Forgent Power has filed to offer Class A common stock in the United States, aiming to raise as much as $1.62 billion. The company plans to list on the New York Stock Exchange as FPS. The proposed offering totals 56 million shares, with specific allocations from the company and selling shareholders. Forgent reported substantial revenue growth year o…
Brazil closed 2025 with a current account deficit equal to 3.02% of GDP, almost unchanged from 3.03% in 2024, central bank figures show. The gap narrowed from an earlier widening to nearly 3.7% of GDP and remained mostly financed by foreign direct investment, which totaled 3.41% of GDP for the year. December data showed a narrower-than-expected cur…
Once Upon a Farm, the organic children’s food company co-founded by actor Jennifer Garner, filed to go public in the U.S., targeting a valuation of up to $764.4 million and seeking to raise nearly $209 million by offering about 11 million shares at $17 to $19 apiece. The company will list on the New York Stock Exchange under the symbol OFRM and has…
IonQ announced plans to acquire SkyWater Technology in a transaction valued at about $1.8 billion, a move that lifted IonQ and SkyWater shares. The deal, offering $15.00 cash and $20.00 in IonQ common stock per SkyWater share, is intended to combine IonQ’s quantum computing capabilities with SkyWater’s U.S.-based semiconductor manufacturing to form…
Canaccord Genuity on January 26, 2026 reiterated a Buy rating on Pacific Biosciences of California (NASDAQ:PACB) and held a $3.00 price target, reflecting roughly 16% upside from the stock's then-current price of $2.58. The share price has rallied recently, trading close to a 52-week high after a strong week of gains. The company reported prelimina…
Canaccord Genuity reaffirmed a Hold rating and a $30 price objective on Caris Life Sciences (NASDAQ: CAI) following the company’s preliminary fourth-quarter and full-year 2025 results. The preliminary numbers outpaced both Canaccord’s estimates and the FactSet consensus by roughly 5% even when omitting revenue from prior period true-ups. Stronger-t…
Canaccord Genuity has reiterated its Buy rating on GRAIL, Inc. (NASDAQ: GRAL) and maintained a $105.00 price target following the company’s preliminary fourth-quarter and full-year 2025 results. The reaffirmation comes as GRAIL reported substantial growth in Galleri testing volume and provided 2026 revenue guidance above analyst expectations at the…
Canaccord Genuity has reiterated a Buy rating on Guardant Health (GH) and maintained a $125.00 price target after the company released preliminary fourth-quarter 2025 results that outperformed both the firm's estimates and the FactSet consensus. The results were driven by growth in Oncology and Shield test volumes, and Canaccord notes Guardant rema…
Forgent Power Solutions Inc. submitted a registration for an initial public offering on the New York Stock Exchange under the symbol FPS. The planned offering amounts to 56 million Class A shares, with a proposed price range of $25.00 to $29.00 per share. The company intends to use proceeds from its portion of the sale to buy common units of its LL…
Santacruz Silver Mining Ltd. saw its stock climb 7% Monday after the company released fourth-quarter 2025 production figures and as silver prices pushed above $110 per ounce. Q4 consolidated output rose on a quarter-over-quarter basis driven by a notable recovery at the Bolívar mine following a May 2025 flooding event, while full-year 2025 producti…
A widespread winter storm delivering snow, sleet and freezing rain left more than 823,000 homes and businesses without electricity early Monday across regions stretching from the Ohio Valley and mid-South to New England. Nashville Electric Service and Entergy were among the hardest hit, while Duke Energy anticipated outages to rise through late Sun…
U.S. stock futures edged slightly lower Monday as traders entered a week that features a Federal Reserve meeting and major tech earnings. Several individual stocks moved notably in premarket trade on merger activity, government investment reports, shifts in commodity prices and corporate announcements, with gold producers and some energy and tech n…
BofA Securities opened coverage of Belite Bio, Inc. ADR (NASDAQ: BLTE) with a Buy rating and a $195 price target, implying roughly an 18% upside from the stock's last quoted price of $164.58. The firm emphasized the commercial opportunity for tinlarebant in Stargardt disease type 1 following positive Phase 3 data, while the company has also priced …
BofA Securities opened coverage of Piper Sandler (NYSE:PIPR) with an Underperform rating and a $385.00 price target, citing constrained potential for outsized EPS growth versus peers tied to larger deals. The firm’s estimates sit below consensus for fiscal years 2026 and 2027, even as Piper Sandler recently posted a significant third-quarter 2025 e…
BofA Securities launched coverage of Moelis (NYSE: MC) with a Neutral rating and an $81 price target, noting the boutique advisory firm's concentrated exposure to M&A revenue and its position as the 14th-largest global M&A advisor. The bank expects deal activity to pick up, but sees relatively more attractive risk/reward profiles elsewhere in its i…
Rothschild Redburn upgraded Meta Platforms Inc. from Neutral to Buy and lifted its price target to $900 from $740, arguing that the stock's long-term upside outweighs short-term spending risks. The firm raised FY26 cost and capital-expenditure estimates, warning of an earnings headwind and a potential temporary dip in consensus EPS to roughly $27-2…
BofA Securities has begun coverage of Evercore Partners (NYSE: EVR) with a Buy rating and a $435.00 price target. The brokerage points to the firm’s standing among boutique investment banks, its ranking in M&A league tables and its private capital business as reasons for optimism. The price objective implies roughly 20% upside from current trading …
BofA Securities began coverage of Lazard (LAZ) with a Buy rating and a $65 price objective, noting the company's significant asset management contribution to revenue, cyclical M&A tailwinds, and progress on a multi-year turnaround. The firm highlighted Lazard's dividend history, recent AUM growth, and management appointments while UBS initiated cov…
